Search

Ernandez, J., S. Kaul, A. Fleishman, R. Korets, P. Chang, A. Wagner, S. Kim, et al. 2022. Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy.

Liu, S., Z. Wang, X. Long, A. Fleishman, X. Huang, Q. Wu, B. Gershman, and A. F. Olumi. 2022. Single Black Men Have the Worst Prognosis With Localized Prostate Cancer.

Gulati, R., B. Jiao, R. Al-Faouri, V. Sharma, S. Kaul, A. Fleishman, K. Wymer, et al. 2024. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging As First-Line Screening for Prostate Cancer : A Decision Model Analysis.

Perez-Londono, A., F. Ramos, A. Fleishman, S. Kaul, R. Korets, M. Johnson, A. F. Olumi, L. Tsai, and B. Gershman. 2025. Predicting Cancer Detection Rates from Multiparametric Prostate MRI Beyond the PI-RADS Classification System.

San Francisco, I. F., W. C. DeWolf, S. Rosen, M. Upton, and A. F. Olumi. 2003. Extended Prostate Needle Biopsy Improves Concordance of Gleason Grading Between Prostate Needle Biopsy and Radical Prostatectomy.

Kuten, A., A. Olumi, J. Goldsmith, R. A. Monahan-Earley, A. M. Dvorak, and E. M. Genega. 2004. Pathologic Quiz Case. A Symptomatic Renal Tumor. Juxtaglomerular Cell Tumor.

San Francisco, I. F., M. M. Regan, A. F. Olumi, and W. C. DeWolf. 2004. Percent of Cores Positive for Cancer Is a Better Preoperative Predictor of Cancer Recurrence After Radical Prostatectomy Than Prostate Specific Antigen.

Zhang, X., T. G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi. 2004. Persistent C-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer.

Halperin, T. J., S. A. Slavin, A. F. Olumi, and L. J. Borud. 2007. Surgical Management of Scrotal Lymphedema Using Local Flaps.

Li, W., X. Zhang, and A. F. Olumi. 2007. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating C-Fos/C-Jun Heterodimers and Repressing C-FLIP(L).